In the News
PPD signs new service agreement with Pfizer
Under the agreement, PPD to provide drug development services to advance Pfizer’s portfolio.
PPD inks new deal with Pfizer
Builds on existing relationship, in which PPD has provided expertise in clinical development and laboratory services for Pfizer, including across multiple therapeutic areas.
Moderna enters P3 trials for vaccine, with $483M BARDA push
Moderna is collaborating with PPD to conduct the trials.
Two Wilmington firms involved in Moderna’s Phase 3 COVID vaccine study
PPD contributes a variety of clinical development and laboratory services, including strategic expertise to the study design, patient-enrollment epidemiology modeling and biostatistics.
PPD expands lab test work to boost pandemic vaccine, drug trial research
PPD® Laboratories has developed five new molecular, serology and functional assays designed expressly for COVID-19 vaccine and therapy development programs.
Data review for today and the next generation
Robert King, Hunter Everton and Philip Bartle discuss how to tackle data reporting challenges while significantly reducing both time and cost.
CAR-T Cell Therapy in Clinical Trials
Panteli Theocharous discusses the three major themes that have emerged in 2020 in response to the sharpened focus on advancing the development of CAR-T therapies.
The limits of light obscuration
Brent Denton, John Bak and Jonathon Salsbury discuss how light obscuration testing is the preferred method of sub-visible particle quantification, but is not suitable for every preparation.
PPD boosts digital trial work amid pandemic
PPD is extending its digital clinical trial offering to support its biopharma clients' R&D as life science companies continue to find workarounds on trial delays.
